Pre-made Relfovetmab biosimilar ( Feline Whole mAb, anti-NGFB therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-477
Anti-NGFB therapeutic antibody (Pre-made Relfovetmab biosimilar,Feline Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Reslizumab is a humanized monoclonal antibody against human interleukin-5 (IL-5). Reslizumab binds specifically to IL-5, a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. By binding to human IL-5, it blocks its biological function; consequently survival and activity of eosinophils are reduced. The benefits with reslizumab are its ability to reduce the exacerbation rate and improve lung function and asthma-related quality of life in patients with severe eosinophilic asthma (with blood eosinophil count ≥ 400 cells/μL) and with at least one previous asthma exacerbation in the preceding year. The most common side effects are increased blood creatine phosphokinase, myalgia and anaphylactic reactions.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-NGFB therapeutic antibody (Pre-made Relfovetmab biosimilar,Feline Whole mAb)|
|Format||Feline Whole mAb|
|Highest_Clin_Trial (Jan '20)||Unknown|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|